Sign in to our online system or register for a new account to submit a letter of intent.
*The deadline for submitting applications to the Rapid Response: Canada 2018 program has now passed*
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments.
The Rapid Response: Canada is seed funding. Preliminary or supporting data is not required. Projects can be from $10,000 to $200,000.
NEW for 2018:
Goal: To provide seed funding for novel, high-risk, high-reward, translational research that will accelerate the development of therapeutics for neurodegenerative diseases of aging.
Funding: A maximum of $200,000 over up to 18 months per project
Applicant Eligibility: Eligible Principal Applicants must be working in Canada at least 30% of the time at or above the level of Postdoctoral researcher, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada.
If the Principal Applicant is not appointed at the institution from which they are applying, they need to apply with a research supervisor (an “Administrative Supervisor”) who is at or above the level of Assistant Professor or equivalent, with an appointment at the institution from which they are applying.
Applicants may appear in any role on any number of projects.
Project Eligibility: Projects must meet two conditions to be eligible:
*Preliminary or supporting data is not required for this program
Please refer to What We Fund for Institute definitions of neurodegenerative diseases of aging, translational research, therapeutic, and tool.
The Rapid Response program will have multiple calls per year, alternating between two different disease groups (outlined below). Applicants should apply to the group best suited to their project.
|Alzheimer’s & Related Diseases:||Parkinson’s & Related Diseases:|
|o Alzheimer’s disease||o Parkinson’s disease|
|o Frontotemporal dementia||o Dementia with Lewy bodies|
|o Mild cognitive impairment||o Multiple system atrophy|
|o Vascular contributions to the above||o Progressive supranuclear palsy|
|o Prodromes to the above||o Vascular contributions to the above|
|o Prodromes to the above|
The Institute welcomes additional inquiries about this program, including whether a potential idea is in scope. For questions related to the Alzheimer’s & Related Diseases program please contact Rene Prashad at firstname.lastname@example.org or 416-967-7835. For questions related to the Parkinson’s & Related Diseases program, please contact Matthew Sacheli at email@example.com or 416-967-7828.
There are two stages of the application process:
An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited.
|Alzheimer’s & Related Diseases:|
|Program opens:||February 1, 2018|
|Letter of Intent deadline:||April 19, 2018 at 2:00pm EDT|
|Proposal deadline:||August 8, 2018 at 2:00pm EDT|
|Anticipated award notification:||October 2018|
|Parkinson’s & Related Diseases:|
|Program opens:||June 2018|
|Letter of Intent deadline:||September 2018|
|Proposal deadline:||December 2018|
|Anticipated award notification:||February 2019|
|*Dates subject to change|
The Institute will hold a Program Information Webinar to provide further details on the program and answer any questions. However, if you have questions specific to your project (e.g., project scope), we encourage you to contact us.
Alzheimer’s & Related Diseases: March 8, 2018 at 1:00pm EST**
Parkinson’s & Related Diseases: July 20, 2018 at 1:00pm EDT**
Registration link will be provided closer to the date
|**Date subject to change|